Synthesis of a Ruthenium(II) Compound based on 5‐(2‐Pyrimidyl)‐1H‐tetrazole for Photodynamic Therapy

Abstract

Ru II compounds have been universally investigated due to their unique physical and chemical properties. In this paper, a new Ru II compound based on 2,2′‐bipy and Hpmtz [2,2′‐bipy = 2,2′‐bipyridine, Hpmtz = 5‐(2‐pyrimidyl)‐1H‐tetrazole], namely [Ru(2,2′‐bipy) 2 (pmtz)][PF 6 ] · 0.5H 2 O was prepared and characterized by elemental analysis, IR and single‐crystal X‐ray diffraction. [Ru(2,2′‐bipy) 2 (pmtz)][PF 6 ] · 0.5H 2 O shows a mononuclear structure and forms a three‐dimensional network by non‐classic hydrogen bonds. The ability of generation of ROS (reactive oxygen species) makes it has a low phototoxicity IC 50 (half‐maximal inhibitory concentration) after Xenon lamp irradiation on Hela cells in vitro. The results demonstrate that [Ru(2,2′‐bipy) 2 (pmtz)][PF 6 ] · 0.5H 2 O with high light toxicity and low dark toxicity may be a potential candidate for photodynamic therapy.